Bodyport Cardiac Scale Cleared by FDA for Fluid Management Assessment

August 9, 2022—Bodyport, a San Francisco, California–based digital therapeutics company addressing complex chronic conditions, announced that its noninvasive biomarker platform, the Bodyport Cardiac Scale, received FDA 510(k) clearance.

According to the company, the Cardiac Scale solution enables patients with fluid management conditions, such as heart failure and kidney disease, to noninvasively assess measures of heart function and fluid status in the same step they take to measure their weight.

The company further explained that Cardiac Scale was designed to seamlessly integrate into a patient’s daily life by not requiring a wearable device or surgical implant and leveraging a familiar form factor and existing habit of daily self-weighing.

Each time a patient steps on the Cardiac Scale, advanced sensors and algorithms measure key hemodynamic biomarkers. The device then sends the data over a cellular network to care teams, providing a window into patient status that enables efficient and effective care. The Cardiac Scale allows optimized interventions tailored to the patient.

“Successful heart failure management requires frequent access to meaningful information, such as fluid status, that is sometimes difficult to gauge by both providers and our patients,” commented Michael Fong, MD, in the company’s press release.

Dr. Fong, who is Co-Founder of the Advanced Heart Failure and Cardiomyopathy Clinic at Keck Medical Center of USC in Los Angeles, California, continued, “During our clinical study using the Bodyport Cardiac Scale, we found patients more engaged and our clinical team better empowered to make timely, individualized treatment adjustments to get ahead of changes in a patient’s condition before they worsen. We are excited about what we saw in the study, the interventions this has led to for some of our patients, and the potential impact it will have for our entire heart disease population.”

Corey Centen, Co-Founder, President, and CTO of Bodyport, added, “The Bodyport Cardiac Scale is a significant step forward in the standard of care for the remote management of patients with cardiorenal conditions. By providing a longitudinal view of fluid status, care teams can more effectively manage their patients through simple, optimized lifestyle and medication adjustments.”